INTRODUCTION
Respiratory syncytial virus (RSV) is a ubiquitous paramyxovirus and is responsible for severe lower respiratory tract infections in human infants. There is no vaccine currently available, although various approaches have been investigated. Clinical trials with a formaldehydeinactivated vaccine in the mid 1960s failed to demonstrate protection and frequently led to enhancement of subsequent natural infection (Fulginiti et al., 1969; Kim et al., 1969) . A later trial with a parenterally administered live RSV vaccine also failed to protect (Belshe et al., 1982) . Both vaccines nevertheless induced RSV-specific serum antibodies, suggesting that humoral immunity may not be sufficient to protect against disease. Although passive transfer studies in animal models have shown that RSV-specific antibodies can protect against experimental infection (Taylor et al., 1984; Walsh et al., 1984; Prince et aL, 1985a, b) , clinical infection of human infants most usually occurs in the presence of maternal neutralizing antibody (Beem, 1967; Parrott et al., 1973; Lamprecht et al., 1976) . t Present address: Department of Immunology, Research Institute of Scripps Clinic, 10666 North Torrey Pines Road, La Jolla, California 92037, U.S.A. 0000-8319 © 1989 SGM In the light of these observations, knowledge of the role of cellular immunity in protection against RSV should prove valuable. Anti-RSV cytotoxic T cell (Tc) responses have been identified in mice (Bangham et al., 1985; Taylor et al., 1985) and man (Bangham & McMichael, 1986; Isaacs et al., 1987) , and there is evidence that cell-mediated immunity is important for protective immunity in man (Fishaut et al., 1980) . Passive transfer of memory T cells has been shown to clear persistent RSV infections in immunodeficient mice , and Tc have recently been implicated both in clearance of infection and augmentation of lung pathology in RSV-infected mice (Cannon et al., 1988) .
The recent availability of recombinant vaccinia viruses (VVs) expressing single RSV genes King et al., 1987) has enabled identification of the RSV nucleoprotein (N) as a target antigen for mouse and human Tc (Bangham et al., 1986) , and Pemberton et al. (1987) have demonstrated that a VV recombinant expressing the RSV fusion protein (F) can prime for RSV-specific mouse Tc, indicating that F is a target antigen for Tc. Furthermore, Wertz et al. (1987) have shown that mice primed with a VV-F recombinant are protected against intranasal RSV challenge. Following up these observations, we demonstrate in this paper that F-specific Tc can also be induced by infection with RSV, both in mice and humans. We have developed mouse Tc clones and a human Tc line that recognize targets infected with VV recombinants expressing the RSV F gene. Our earlier work had indicated that Tc from mice primed with a VV-F gene recombinant were strongly RSV strain-specific (Pemberton et al., 1987) . We have confirmed this finding, but found in contrast that the F-specific Tc clones from RSV-primed mice were cross-reactive for RSV strains of different serogroups. This divergence of the mouse F-specific Tc repertoire was apparently a consequence of the method and route of priming.
METHODS
Viruses. The human A2, 8/60, and 18537 strains of RSV were provided by Dr E. J. Stott (Institute for Animal Health, Compton Laboratory, Compton, U.K.). These viruses were grown in HEp-2 cells and stored in liquid nitrogen as previously described (Bangham & Askonas, 1986) ; infectivity was measured by microplaque immunoperoxidase assay . Recombinant VVs expressing RSV A2 genes were kindly provided by Professor G. W. Wertz (University of Alabama, Birmingham, Ala., U.S.A.). VF325 and VF317 contain the RSV F gene (Pemberton et al., 1987; , as does VF250, and VV 1A contains the RSV 1A gene (Pemberton et al., 1987) . VF325 and VF317 are both effective in priming RSV F-specific immune responses in mice , and VF325 was used here (see below). However, VF317 was used for infection of target cells in mouse Tc assays (see below), as it is a higher expresser of the RSV F gene (Pemberton et al., 1987) . A third recombinant virus, VF250, was found to be most effective for infection of Epstein-Barr virus-transformed human B cells (BCL) as targets in the assay for human Tc (see below).
VVs were grown and assayed in HEp-2 cells as previously described (Bangham et al., 1986) . Mice. Specific pathogen-free BALB/c mice, aged 2 to 3 months, were bred at the National Institute for Medical Research, London, U.K. In these experiments, mice were primed by intraperitoneal inoculation of 2 x 107 p.f.u. VF325, or by intranasal infection with approx. 105 p.f.u. RSV A2.
Culture medium. Mouse spleen cells and T cells were grown in RPMI 1640 containing 10~ foetal calf serum, 60 p.g/ml penicillin, 100 ~tg/ml streptomycin, 300 p-g/ml glutamine and 50 p.M 2-mercaptoethanol. This medium was designated RPMI/10. Crude interleukin 2 (IL-2) was provided by 48 h supernatants from concanavalin Astimulated rat spleen cell cultures.
Human peripheral blood mononuclear cells (PBM) and T cells were grown in RPMI/10. Human T cell cultures were supplemented with 30~ crude human IL-2, provided by MLA144 cell culture supernatant (Rabin et al., 1981) .
Establishment and maintenance of mouse T cell lines; phenotype analysis. Spleen cell cultures were initiated as previously described (Bangham et al., 1985) from mice primed up to 6 months earlier with RSV A2 or VF325. T cell lines were derived by repeated in vitro passage with antigen stimulation every 7 days in 25 cm 2 tissue culture flasks (Nunc). T cells (3 × 106) were cultured in 20 ml RPMI/10 with 2 x 107 syngeneic X-irradiated (3000 tad) spleen cells infected with RSV A2 at an m.o.i, of 0.1 p.f.u./cell. After four or five passages, the cultures were supplemented every 3 to 4 days with 10 % crude IL-2. For cytotoxicity assays these lines were used after a minimum of five passages.
The line derived from RSV A2-primed mice, designated MJC-A2, has been described (Cannon et al., 1988) . Briefly, MJC-A2 T cells were 80 ~ Lyt 2 + and 20~ L3T4 +; assays for helper T cell function showed that MJC-A2 T cells produced IL-3, but not IL-2. The F-specific line from (VF325-primed mice), designated MJC-F, was also predominantly Lyt 2 +, but with a small number of L3T4 + T cells (less than 10%). Assays for MJC-F helper T cell function were not carried out.
Mouse Tc clones. Tc clones were isolated 3 to 5 days after the first in vitro antigenic stimulation of spleen cells from RSV A2-primed BALB/c mice. T cells were distributed at limiting dilution in microwell plates (Flow Laboratories) with syngeneic RSV-infected X-irradiated spleen cells (5 × 105/well). These cultures were supplemented with 10% crude IL-2 at days 0 and 7, and clones were selected at approx, day 14. Tc clones were passaged every 7 days as described above.
Cytotoxicity assays. The 51Cr-release assay for RSV-specific Tc has been described (Bangham et al., 1985) . Target cells were (i) BALB/c fibroblasts infected for 24 h with RSV A2 or 8/60 at an m.o.i, of 2 p.f.u./cell, (ii) BCH4 cells, a BALB/c fibroblast line persistently infected with RSV Long strain (Fernie et al., 1981) , and (iii) BALB/c fibroblasts persistently infected with RSV 18537 (M. J. Cannon, unpublished results). All Tc clones and lines were strongly cross-reactive for RSV A2 and Long strains, and consequently BCH4 cells were commonly used as positive control targets for A2-specific To. Uninfected BALB/c fibroblasts were used as a negative control.
The antigen specificity of Tc clones D5 and H11 a was established in S lCr-release assays using P815 (H-2 d) rnastocytoma cells infected for 4 h with recombinant vaccinia virus VF317 at an m.o.i, of 10 p.f.u./cell.
Human RSV-specific Tc lines; Tc assay. Human Tc lines were derived from PBM of healthy adult volunteers, as previously described (Bangham & McMichael, 1986) . Briefly, 3 × 106 stimulator PBM, separated from heparinized venous blood on Lymphocyte Separation Medium (Flow Laboratories) were incubated with 3 × 106 p.f.u. RSV A2 for 90 min at 37 °C and then suspended in 8 ml RPMI/10 with 107 autologous responder PBM. One weeklater, survivingcellsweredistributedat0-5 x 106tol × 106cells/wellina24-weUplate(Costar)inRPMI/10 containing 30% crude human IL-2. X-irradiated (2000 rad) autologous BCL (1 × 10 s to 5 × 105), which had been persistently infected with RSV A2 (Bangham & McMichael, 1986) , were added to each well. The lines were restimulated in this way once each week, supplemented with fresh RPMI/10 plus 30% crude human IL-2 three times each week, and used in a 5 h 5 iCr.release Tc assay after at least two passages. Target cells used in human Tc assays were autologous BCL persistently infected with RSV A2, or infected overnight with recombinant VVs (3 to 10 p.f.u./cell).
RESULTS

Recognition of RSV F by mouse Tc clones
Of five Tc clones isolated, two were F-specific (clones D5 and H1 la). These clones possessed essentially the same characteristics, and consequently only clone H1 la is described here. This clone lysed P815 targets infected with RSV A2 or VV recombinant VF317, which expresses the RSV F gene, but failed to lyse uninfected P815 cells or P815 cells infected with VV1A, a recombinant which expresses the RSV 1A gene (Fig. 1 a) . In contrast, a Tc line, MJC-A2, failed to lyse VF317-infected targets, although it was strongly lytic for RSV A2-infected P815 cells (Fig. 1 b) . The RSV antigen specificity of the Tc line MJC-A2 has not been determined (Cannon et al., 1988) . MJC-A2 cells also failed to lyse P815 cells infected with recombinant VVs expressing the RSV nucleoprotein, major glycoprotein, 1C or a partial matrix protein gene construct encoding amino acid residues 88 to 257. et al., 1985) . The serogrouping of the strains used in this study is summarized in Table 1 . Tc line MJC-A2 was found to be strongly cross-reactive for RSV 8/60 (serogroup 2) ( Fig. 2a) , as was the RSV F-specific Tc clone H 11 a (Fig. 2b) . MJC-A2 cells also efficiently lysed BALB/c fibroblasts persistently infected with RSV 18537, another serogroup 2 strain (Fig. 2c) , but Tc clone H1 la showed reduced lysis of 18537-infected targets (Fig. 2d) Mufson et al. (1985) .
RSV strain specificity of Tc clone Hlla and Tc line MJC-A2 RSV strains can be divided into two serogroups on the basis of recognition patterns of a series of monoclonal antibodies against the viral N, large glycoprotein, matrix protein and F (Mufson
. A possible explanation for this observation was provided by F-specific immunofluorescence assays, which showed that less than 10 % of the 18537-infected cells expressed detectable cell surface F (data not shown). Poor expression of F might not affect lysis by MJC-A2 cells which are known not to be F-specific.
t All Tc tested were cross-reactive for serogroup 1 strains, i.e. Long and A2. The Long Strain was used only in the form of persistently infected BCH4 cells.
RSV strain specificity of an F-specific line derived from VF325-primed mice
We have shown that RSV F-specific mouse Tc clones D5 and H1 la recognize RSV strains of both serogroups I and 2 (see above), as does MJC-A2, a Tc line of undefined antigen specificity. In contrast, MJC-F, an F-specific T cell line derived from mice primed with a VV recombinant expressing the RSV F gene, exhibits a considerable degree of strain specificity. MJC-F Tc strongly lysed BCH4 cells (Long strain; serogroup 1), but showed greatly reduced lysis of 8/60infected fibroblasts (Fig. 3 a) , confirming the results of Pemberton et al. (1987) , who also found that RSV 18537-infected targets were poorly lysed by Tc from mice primed with a VV-F recombinant virus. MJC-A2 cells strongly lysed 8/60-infected targets in the same assay (Fig. 3 b) , indicating that the fibroblasts were efficiently infected by RSV 8/60. 
IP
Recognition of RSV F by human Tc line IH.K2
Previous work has shown that of four human RSV-specific Tc lines assayed, all four recognized the RSV N in a self-restricted fashion (Bangham et al., 1986 ; C. R. M. Bangham, unpublished results) . In this study, we show that one of these lines, IH. K2, also recognizes the RSV F. IH. K2 Tc lysed autologous BCL persistently infected with RSV A2, and BCL infected with VV recombinant VF250 (Fig. 4) . Recognition of the RSV F was also self-restricted (not shown). Targets infected with the VV1A recombinant were not lysed. Flow cytometric analysis indicated that the IH. K2 Tc were > 99 % CD8 + (data not shown), a result consistent with major histocompatibility complex (MHC) class I restriction.
The recognition of both the N and the F by IH. K2 Tc indicates either the presence of crossreactive Tc, or the presence of at least two distinct populations, one directed against N and the other against F. We consider the latter explanation to be the most likely, not only because the IH. K2 line is undoubtedly polyclonal, but also because there is no prior evidence of antigenic identity (serological or cellular) between the two proteins. 
DISCUSSION
An internal RSV antigen, N, has been identified as a target antigen for Tc in both mouse and man (Bangham et aL, 1986) ; in this report we describe two mouse Tc clones (D5 and H1 la) and a human Tc line (IH. K2) that recognize the RSV F, showing that anti-RSV Tc are also directed against a transmembrane glycoprotein. Although F is expressed on the surface of infected cells, the results reported here do not necessarily imply that Tc recognize intact forms of F; recognition may be subject to antigen processing mechanisms similar to those thought to be involved in Tc recognition of internal viral proteins (Townsend et al., 1985; Townsend, 1987) .
The two mouse F-specific Tc clones were identified from a total of five RSV-specific clones isolated, suggesting that induction of F-specific memory Tc is a relatively frequent event following RSV infection of mice. In contrast, only one of four human polyclonal Tc lines recognized the RSV F, suggesting that F-specific Tc form a minor component of the human RSV-specific Tc response. Previous work has indicated that RSV N-specific Tc form an important part of the human Tc response, whereas the mouse response gives only low levels of N-specific target cell lysis (Bangham et al., 1986 ). It appears, therefore, that while both the human and mouse RSV-specific Tc repertoires include N-and F-specific Tc, there may be significant quantitative differences.
With mice, we have also described a Tc line (MJC-A2, derived from RSV A2-primed BALB/c mice) that fails to lyse targets infected with recombinant VVs expressing the RSV N or F genes, indicating that at least one other RSV antigen is a major target for mouse Tc. The nature of this antigen(s) remains undetermined; we have found no evidence that MJC-A2 Tc recognize the RSV large glycoprotein, or the 1A, 1C or partial matrix gene products. Definition of other gene products as target antigens for RSV-specific Tc awaits the production of further VV recombinants.
It has become increasingly apparent that host MHC alleles play a major role in determining the Tc repertoire, i.e. precisely which epitope(s) on a viral antigen is recognized by antiviral Tc (Townsend et al., 1986; Pala & Askonas, 1986; Bastin et al., 1987; Taylor et al., 1987) . On this basis, one would expect Tc against a given viral antigen (in this case, the RSV F) to exhibit consistent epitope specificity, as long as the host MHC alleles are also consistent. We find, however, that although the F-specific BALB/c Tc line MJC-F (from VF317-primed mice) is strongly strain-specific, as previously shown in this laboratory (Pemberton et al., 1987) , the Fspecific BALB/c Tc clones from RSV-infected mice are RSV strain cross-reactive. The strain specificity of the MJC-F line is seen in spite of a high level of F antigenic relatedness, at least between RSV strains A2 and 18537 (Johnson et al., 1987) . These results suggest that the method and route of priming can also play an integral part in the determination of the RSV F-specific Tc repertoire. VF325-primed mice are known to be protected against RSV A2 infection ; in the light of our findings on the strain specificity of VF325-derived Tc, it would be informative to assess immunity to heterologous RSV strains.
Although F-specific Tc may be of relatively low frequency in humans, our observations could nevertheless have consequences for the development of a vaccine against RSV. Should Tc be involved in protection against RSV infection in humans, it would clearly be important to identify Tc target antigens, and to ensure that a given vaccination strategy incorporates these antigens and induces an RSV strain cross-reactive response. However, it is not clear that induction of RSV-specific Tc would be beneficial for the vaccinee. Recent experiments have shown that although adoptive transfer of Tc lines or clones to RSV-infected mice can rapidly clear pulmonary infection, clearance is accompanied by severe, often lethal, haemorrhagic pneumonia associated with neutrophil infiltration (Cannon et al., 1988) . These observations raise serious questions about the role of TC in RSV immunopathology. Tc have recently been identified in human infants suffering from RSV bronchiolitis (Isaacs et al., 1987) , raising the possibility that Tc are responsible for much of the tissue damage seen in acute bronchiolitis in humans. It is apparent that we need to know more about the specificity and role in vivo of anti-RSV Tc, particularly in human infants, before a safe vaccine can be developed. ( Received 26 February 1988) 
